| 臺大學術典藏 |
2022-02-23T02:12:19Z |
How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?
|
Chen M.-H.; Lu S.-N.; CHIEN-HUNG CHEN; Lin P.-C.; Jiang J.-K.; D’yachkova Y.; Lukanowski M.; Cheng R.; Chen L.-T. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:32Z |
Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan
|
CHIEN-HUNG CHEN; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:31Z |
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan
|
Lu S.-N.; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:31Z |
Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients
|
CHIEN-HUNG CHEN; Chang T.-T.; Cheng K.-S.; Su W.-W.; Yang S.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:26Z |
Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: Identification of potential high HCV endemic areas
|
Su W.-W.; CHIEN-HUNG CHEN; Lin H.H.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:21Z |
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study
|
Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; You S.-L.; Wang L.-Y.; Wang C.-H.; Chen W.J.; Chen C.-J.; Hsieh C.Y.; Lee H.S.; Yang P.M.; CHIEN-HUNG CHEN; Chen J.D.; Huang S.P.; Jan C.F.; Chen T.H.H.; Sun C.A.; Wu M.H.; Chen S.Y.; Chu K.E.; Ho S.C.; Lu T.G.; Wu W.P.; Ou T.Y.; Lin C.G.; Shih K.C.; Chung W.S.; Li C.; Chen C.C.; How W.C. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c
|
Lo C.-C.; Chen M.-T.; Huang K.-C.; Lin C.-H.; Cheng H.-S.; Liao Y.-T.; Hung L.-W.; Lu S.-N.; CHIEN-HUNG CHEN |
